Overview

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis

Status:
Terminated

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

This multicenter randomized, placebo-controlled phase II study will enroll 132 first-line palliative treated subjects with metastatic KRAS wild type CRC. Subjects with histologically confirmed, KRAS wild-type CRC without previous chemo-therapy for metastatic disease will be screened for this study. Approximately 10 sites in Austria will participate in the study. Subjects will be randomized in a ratio of 1:1 into two groups.

Phase:

Phase 2

Details

Lead Sponsor:

Austrian Breast & Colorectal Cancer Study Group

Collaborator:

Merck Gesellschaft mbH, Austria

Treatments:

Cetuximab
Metformin